$Arcutis Biotherapeutics (ARQT.US)$Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older 1 MINUTE AGO, 8:20 AM EDT VIA GLOBENEWSWIRE
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
blessings u : Just completed 922 transactions.
blessings u : Thank you for sharing.